James Wilson

I was diagnosed with hep C in 2004. I had gone to my doctor because I was feeling a bit run down and he took some blood and put me on a vitamin supplement. At the time, I was working part time, studying full time and doing volunteer work. Being so busy, I had forgotten all about the blood test until I was contacted by the health department to inform me that I had been diagnosed hep C positive and to get in touch with my doctor.

I am a little unsure of when I actually contracted hep C. However I now know the factors which put me at risk. I began getting tattoos in 1974 and began using speed intravenously in 1976 until 1999. At the time I began injecting, my friends and I knew nothing of the risks associated with these behaviours. We became aware of HIV in the mid-1980s and we all stopped sharing needles but we still continued to share other injecting paraphernalia.

After I was diagnosed with hep C, I got in touch with as many of my old injecting buddies as I could and told them of my hep C status and advised them to see their doctor.

After completing my studies, I started working in a drug and alcohol service and it was there that I began to realise that I wasn’t Robinson Caruso as far as hep C went, as many of the clients of the service were also hep C positive, and this made me start thinking about treatment.

Six months later, I got a job at a youth accommodation service, where I initially kept the fact that I was hep C positive to myself, but I was starting to really consider having treatment. Then I started bringing information about hep C into work and talking about it to my co-workers. I put up different posters in the office and that sort of thing, so that by the time I did disclose my hep C status, my co-workers had a good understanding of the virus and were supportive of me.

I began treatment for hep C in June 2007, it wasn’t easy but I felt that I was lucky because I had genotype 2 and the treatment only lasted 24 weeks. The treatment consisted of a once weekly injection of pegylated interferon and six tablets of ribaviron daily taken 3 tablets in the morning and 3 at night.

Can you imagine having a flu which lasts for six months? I had absolutely no energy and I felt aches and pains constantly. When I gave myself my weekly injection my temperature would soar and I would be so debilitated that I couldn’t get out of bed.

Up until I began the treatment I had been a fairly heavy drinker but I committed at the outset that I would stop drinking, however I didn’t have much choice as once treatment commenced, I have never felt less like drinking.

Now I am hep C free and feeling good about myself. In fact I feel better than I did 10 years ago.

What I would like to voice about my journey with hep C is that anyone can have the virus, people from all walks of life, but having the virus is not a death sentence and the treatment while not pleasant can be very effective in curing hepatitis C.

Share your story now

For people living with a hepatitis condition, it really helps to know they’re not alone. That’s why we’re inviting people to share their stories.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close